Volatile Acid-Solvent Evaporation (VASE): Molecularly Homogeneous Distribution of Acyclovir in a Bioerodable Polymer Matrix for Long-Term Treatment of Herpes Simplex Virus-1 Infections

<div>Photos of HSV-1infected Vero cells. Each photo is representative of a common field observed for each treatment that was conducted in triplicate. Treatment groups:<b> (A-B) </b>Nontreated controls;<b> (C-D) </b>devices containing 0:100 (w:w) ACV:PCL (VASE).<b> (E-F) </b>devices containing 30:70 (w:w) ACV:PCL (VASE). (<b>G-H)</b> devices containing 30:70 (w:w) ACV:PCL (SID). (<b>I-J)</b> devices containing 50:50 (w:w) ACV:PCL (VASE).<b> (K-L) </b>ACV solution at 25 <i>μ</i>g/mL. All photos in the top row show cells that were mock infected; photos in the bottom row show cells that were infected with HSV-1 (KOS) at an MOI of 1.</div>

Journal of Drug Delivery

fig5

Figure 5

Figure 5: Volatile Acid-Solvent Evaporation (VASE): Molecularly Homogeneous Distribution of Acyclovir in a Bioerodable Polymer Matrix for Long-Term Treatment of Herpes Simplex Virus-1 Infections 

Figure 5 | Volatile Acid-Solvent Evaporation (VASE): Molecularly Homogeneous Distribution of Acyclovir in a Bioerodable Polymer Matrix for Long-Term Treatment of Herpes Simplex Virus-1 Infections 